新疆西部牧业股份有限公司 关于公司自产生鲜乳销售情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 新疆西部牧业股份有限公司（以下简称"公司"）主要经营业务 为乳制品加工与销售、饲料生产与销售、自产生鲜乳生产与销售、外 购生鲜乳收购与销售等。根据《深圳证券交易所上市公司自律监管指 引第 3 号——行业信息披露》的相关规定，公司现对养殖业务月度生 产情况进行公告。 证券代码：300106 证券简称：西部牧业 公告编号：临 2026-010 新疆西部牧业股份有限公司董事会 2026 年 3 月 3 日 1 | 项 | 目 | | 年 2026 | 月 2 | 本月比上月增 减比率（%） | 本月比上年同 期增减比率（%） | | --- | --- | --- | --- | --- | --- | --- | | 自产生鲜乳 | | 生产量（吨） | | 3,100.52 | 0.78% | -4.47% | 特此公告。 ...

上市公司：承德露露（000848），阳光乳业（001318），皇氏集团（002329），贝因美（002570），西 部牧业（300106），品渥食品（300892），熊猫乳品（300898），三元股份（600429），光明乳业 （600597），妙可蓝多（600882），伊利股份（600887），李子园（605337） 相关报告：智研咨询发布的《2026-2032年中国饮料行业市场运营格局及未来前景分析报告》 数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 2025年1-12月，酒、饮料和精制茶制造业企业数（以下数据涉及的企业，均为规模以上工业企业，从 2011年起，规模以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万 元）为5965个，和上年同期相比，减少了65个，同比下降1.08%，占工业总企业的比重为1.13%。 2016-202 ...

Core Viewpoint - The report highlights the growth of industrial enterprises in the Xinjiang Uygur Autonomous Region, indicating a significant increase in the number of large-scale industrial companies and their contribution to the national economy [1]. Group 1: Industrial Growth in Xinjiang - As of January to December 2025, the number of industrial enterprises in Xinjiang is projected to be 5,576, which represents an increase of 438 enterprises compared to the previous year, marking a year-on-year growth of 8.52% [1]. - The industrial enterprises in Xinjiang account for 1.06% of the total number of such enterprises in the country [1]. Group 2: Industry Research and Consulting - Zhiyan Consulting is recognized as a leading industry consulting firm in China, specializing in deep industry research and providing comprehensive consulting services, including industry research reports and feasibility studies [1]. - The firm emphasizes its commitment to delivering high-quality services and market insights to empower investment decisions [1].

证券代码：300106 证券简称：西部牧业 公告编号：临2026-009 新疆西部牧业股份有限公司 2026 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 特别提示： 1.本次股东会无增加、变更、否决提案的情况。 2.本次股东会不涉及变更以往股东会已通过的决议。 3.本次股东会以现场投票和网络投票相结合的表决方式召开。 一、会议召开和出席情况 新疆西部牧业股份有限公司（以下简称"公司"）2026 年第二次临 时股东会于 2026 年 2 月 12 日 14:30 在新疆石河子市开发区北一东路 28 号公司办公楼二楼会议室召开。本次会议采取现场投票与网络投票结合 的表决方式，网络投票由公司委托深圳证券交易所交易系统和互联网投 票系统提供，其中，通过深圳证券交易所交易系统进行网络投票的时间 为 2026 年 2 月 12 日上午 9:15－9:25，9:30－11:30，下午 13:00－15:00； 通过深圳证券交易所互联网投票系统进行网络投票的时间为 2026年2月 12 日上午 9:15 至下午 15:00。会议由公司董事会召集 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于新疆西部牧业股份有限公司 2026 年第二次临时股东会的 法律意见书 国枫律股字[2026]A0056 号 致：新疆西部牧业股份有限公司（贵公司） 1 定的事实真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导 性陈述或者重大遗漏，并承担相应法律责任； 4．本法律意见书仅供贵公司本次会议之目的使用，不得用作任何其他用途。本所 律师同意将本法律意见书随贵公司本次会议决议一起予以公告。 本所律师根据《公司法》《证券法》《股东会规则》《证券法律业务管理办法》《证 券法律业务执业规则》等相关法律、行政法规、规章、规范性文件的要求，按照律师行 业公认的业务标准、道德规范和勤勉尽责精神，对贵公司提供的有关文件和有关事项进 行了核查和验证，现出具法律意见如下： 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司2026年第二次临时股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国 ...

Group 1 - Kailong High-Tech is focusing on the embodied intelligence sector, launching the "Huilingjia" series of robots and dexterous intelligent detection equipment, which are still in the market development stage and have not yet generated revenue [2] - Wuzhou New Spring plans to establish a joint venture with Zhongzhe High-Speed Rail, focusing on the research and manufacturing of high-end equipment bearings, with a registered capital of 60 million yuan [3] - GCL-Poly has not yet received any orders in the "space photovoltaic" sector, which remains in the exploratory stage, and this has not materially impacted the company's performance [5] Group 2 - Guoxuan High-Tech plans to raise no more than 5 billion yuan through a private placement, with proceeds allocated to a 20GWh power battery project and other related initiatives [4] - Xingsheng Zhitu confirmed that its operations are normal and there are no undisclosed significant matters [6] - Nanjin Mining intends to invest 30 million USD to acquire a 10% stake in Eagle Valley Gold Company, pending regulatory approvals [7] Group 3 - Lixun Precision plans to engage in foreign exchange derivatives trading for up to one year, with a cumulative limit of 4.9 billion USD [8] - Heng Rui Medicine's HR091506 tablet application for market approval has been accepted by the National Medical Products Administration, targeting long-term treatment for hyperuricemia in gout patients [11] - Wen's shares reported a revenue of 4.698 billion yuan from pork sales in January 2026, a decrease of 11.17% month-on-month [12] Group 4 - Yingjixin reported a net profit of 177 million yuan for 2025, a year-on-year increase of 42.81% [13] - Xibu Muye's fresh milk production in January 2026 was 3,076.65 tons, a year-on-year decrease of 2.54% [15] - Alibaba Health's shareholding in Shuyupingmin has decreased to 5.39% following a series of share reductions [16] Group 5 - Jiangfeng Electronics plans to acquire control of Kaide Quartz, with stock resuming trading on February 6 [17] - Runze Technology is planning to issue convertible bonds to acquire minority stakes in Runhui Technology, leading to a stock suspension starting February 6 [18] - Tianqimo is planning to purchase shares of Dongshi Automotive Technology Group, resulting in a stock suspension from February 6 [19] Group 6 - ST Lifang's stock has surged by 314.93% from January 20 to February 5, leading to a suspension for risk assessment [20][21]

3、美团：拟7.17亿美元收购叮咚 美团2月5日公告，公司拟以7.17亿美元收购中国大陆领先的生鲜电商企业叮咚的全部已发行股份。根据 协议，转让方可从目标集团提取不超过2.8亿美元的资金，但需确保目标集团净现金不低于1.5亿美元。 此次收购将使目标公司成为美团的间接全资附属公司，其财务业绩将并入美团的财务报表。 4、天汽模：筹划购买东实股份股权 股票停牌 天汽模2月5日公告，公司正在筹划通过发行股份及支付现金的方式购买东实汽车科技集团股份有限公司 股权并募集配套资金，预计构成重大资产重组。公司股票自2026年2月6日起停牌，预计在不超过10个交 易日内披露交易方案。若公司未能在上述期限内召开董事会审议并披露交易方案，公司股票将于2026年 3月2日开市起复牌并终止筹划相关事项。 5、两连板协鑫集成：公司暂未获得"太空光伏"领域的相关订单 今日聚焦 1、百度集团：董事会已批准一项新的50亿美元股份回购计划 百度集团2月5日公告，董事会已批准一项新的50亿美元股份回购计划及一项股息政策，旨在进一步提升 股东回报。 2、太极实业：子公司十一科技预中标华虹FAB9B项目投标报价37.78亿元 太极实业2月5日公告，子 ...

Group 1 - Company Jianhui Information plans to acquire 38% equity in Boke Guoxin for RMB 73.71 million, increasing its stake from 32% to 70%, making Boke Guoxin a subsidiary [1] - Company Guangshengtang's innovative drug GST-HG141 for hepatitis B has completed the enrollment of 578 participants in its Phase III clinical trial [2] - Company Hongjing Optoelectronics is establishing a partnership with a target scale of RMB 290 million, contributing RMB 3 million as a limited partner [3] Group 2 - Company Hongchang Technology intends to acquire 21% equity in Liangzhi Joint, which will make it the controlling shareholder with a 51% stake [4] - Company Xiexin Integrated has not yet received any orders in the "space photovoltaic" sector, which remains in the exploratory phase [5] - Company Xianheng International plans to reduce its shareholding by up to 3%, amounting to a maximum of 12.28 million shares [6] Group 3 - Company Furuijia plans to reduce its repurchased shares by up to 2%, totaling 18.93 million shares [7] - Company Tianqimo is planning to issue shares and pay cash to acquire assets, leading to a temporary suspension of its stock [8] - Company Shuangqiang Technology's director plans to reduce his holdings by up to 0.32% [9] Group 4 - Company Bairun plans to adjust the conversion price of its bonds due to stock prices falling below 85% of the conversion price [11] - Company Dongnan Network has won an EPC project worth RMB 994 million [12] - Company Anhui Energy has appointed Xu Wengong as the new general manager following the resignation of Fang Shiqing [13] Group 5 - Company Lijun plans to invest up to USD 3 million to establish subsidiaries in Hong Kong and Peru [14] - Company Zhenghe Ecology has signed a strategic cooperation agreement with the government of Beijing's Miyun District [15] - Company First Venture has elected Guo Chuan as the chairman of its board [16] Group 6 - Company Changxin Bochuang's shareholder has terminated an agreement to transfer 14.5 million shares [17] - Company Hengrui Medicine's HR091506 tablet application has been accepted by the National Medical Products Administration [18] - Company Hengrui Medicine's SHR-1894 injection has received approval for clinical trials [20] Group 7 - Company Longshen Rongfa has obtained a medical device production license [21] - Company Western Securities reported that its new borrowings exceeded 20% of its net assets [22] - Company Rongfa Nuclear Power's subsidiary has won a project worth RMB 101 million [23] Group 8 - Company Taiji Industry's subsidiary has a pre-bid for the Huahong FAB9B project with a bid amount of RMB 3.778 billion [24] - Company Suzhou High-tech plans to increase its investment in a subsidiary by RMB 780 million through a debt-to-equity swap [26] - Company Electric Power Investment's vice president has resigned due to work changes [27] Group 9 - Company Hengwei Technology reported a 30.13% increase in net profit for 2025 [28] - Company Fangsheng Pharmaceutical's subsidiary has received a drug production license [29] - Company Pilin Bio's subsidiary has received a notice for clinical trial acceptance for a hemostatic drug [31] Group 10 - Company Zhongxin Fluorine Material has received approval for a stock issuance to specific investors [32] - Company Shanhe Intelligent expects a total transaction amount with related parties to be RMB 1.197 billion in 2026 [33] - Company Warner Pharmaceutical's partner has completed Phase I clinical trials for a new drug [34]

智通财经APP讯，西部牧业(300106.SZ)公告，公司2026年1月自产生鲜乳3076.65吨，同比上年减少 2.54%。 ...

智通财经APP讯，西部牧业(300106.SZ)公告，公司2026年1月自产生鲜乳3076.65吨，同比上年减少 2.54%。 ...